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Objective. The aim of the study was to evaluate the prevalence of and risk factors for lower limb amputation in a specialist foot
clinic-based setting.Methods. A retrospective quantitative study was conducted, using clinical and biochemical profiles of diabetic
foot patients attending the High Risk Foot Clinic at The Townsville Hospital, Australia, between January 1, 2011, and December 31,
2013. Results.The total study sample included 129 subjects, comprising 81 males and 48 females with M : F ratio of 1.7 : 1. Twenty-
three subjects were Indigenous Australians, representing 17.8% of the study population.The average age of the cohort was 63.4 years
± 14.1 years [CI 90.98–65.89]. Lower limb amputation was identified as a common and significant outcome (𝑛 = 44), occurring in
34.1%, more commonly amongst the Indigenous Australians (56.5% versus 29.2%; 𝑝 = 0.94, OR 0.94). Risk factors most closely
associated with amputation included diabetic retinopathy (𝑝 = 0.00, OR 4.4), coronary artery bypass graft (CABG) surgery
(𝑝 = 0.01, OR 4.1), Charcot’s arthropathy (𝑝 = 0.01, OR 2.9), and Indigenous ethnicity (𝑝 = 0.01, OR 3.4). Although average
serum creatinine, corrected calcium, and glycosylated haemoglobin A1c (Hba1c) levels were higher amongst amputees they were
statistically insignificant. Conclusions. Lower limb amputation is a common outcome and linked to ethnicity and neurovascular
diabetic complications amongst subjects with diabetic foot ulcer. Further research is needed to identify why risk of lower limb
amputation seems to differ according to ethnicity.
1. Introduction
Diabetes and the diabetic foot ulcer (DFU) have made their
mark in society, with the prevalence of diabetes being four
times higher than all cancers combined [1]. Increased life
expectancies have contributed significantly to this exponen-
tial rise, with diabetes now contributing to 9% of global
mortality, equating to 4 million deaths per year [2, 3]. DFU
occurs as a diabetic complication and involves a multifac-
torial pathogenesis including peripheral neuropathy as the
primary causal factor, together with variable contribution
from peripheral vascular disease (PVD), repetitive trauma,
and superimposing foot infection [4, 5]. Infected DFU is a
major cause of prolonged hospital admission and contributes
over 90% of nontraumatic lower limb amputations (LLAs)
[6, 7], which is more than a million amputations/year [8–10].
Whilst the 1990 St. VincentDeclaration to half LLAs in 5 years
has failed [11], we have instead seen a 50% 5-year mortality
rate amongst diabetic amputees [12–14].
The progressive rise of diabetes is likely to pose a sig-
nificant burden on future society leading to an associated
increase in diabetic amputations [15, 16]. Despite previous
alert to the importance of early detection and management,
prevention practices remain poor, with inconsistent patient
follow-up and management compliance [17, 18]. As a result,
subjects with DFU maintain poorer quality of life, with
higher baseline depression rate, and 5-year mortality rates of
up to 74% [19]. Existing studies have identified Indigenous
ethnicity and presence of microvascular complications as
contributing factors to poor DFU outcomes; however there
is currently limited Australian evidence supporting this [20].
Furthermore there is no current data on the burden of either
amputation or macrovascular outcomes amongst subjects
with DFU in clinic setting in Australia which is home to
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Table 1: Basic study characteristics and prevalence of adverse outcomes amongst the diabetic foot ulcer cohort.
Characteristic Results
Age 63.43 years ± 14.07 years [CI 60.98–65.89]
Sex Males (n = 81; 62.8%); females (n = 48; 37.2%)
Ethnicity Indigenous (n = 23; 17.8%); non-Indigenous (n = 106; 82.2%)
Type of diabetes Type 1 (n = 22; 17.1%); type 2 (n = 107; 82.9%)
Type of ulcer Ischaemic (n = 57; 44.2%); nonischaemic (n = 72; 55.8%)
Clinical outcome Total study sample Ischaemic ulcer cohort Nonischaemic ulcer cohort 𝑝 value, OR [CI]
Amputation (n = 44)—34.1% (n = 20)—35.1% (n = 24)—33.3% p = 0.84, 1.1 [0.52–2.25]
Minor amputation (n = 35)—27.13% (n = 15)—42.9% (n = 20)—57.1% p = 0.50, 0.9 [0.14–2.62]
Major amputation (n = 9)—6.98% (n = 5)—55.5% (n = 4)—44.4% p = 0.50, 1.5 [0.46–4.84]
Indigenous amputations (n = 13)—56.5% (n = 9)—69.2% (n = 4)—30.8% p = 0.94, 0.9 [0.17–5.07]
Ischaemic heart disease (n = 61)—47.3% (n = 31)—54.4% (n = 30)—41.7% p = 0.15, 1.7 [0.83–3.36]
Acute myocardial infarction (n = 27)—20.9% (n = 15)—26.3% (n = 12)—16.7% p = 0.18, 1.8 [0.76–4.20]
Cerebrovascular accidents (n = 19)—14.7% (n = 11)—19.3% (n = 8)—11.1% p = 0.19, 1.9 [0.71–5.13]
Chronic kidney disease (n = 52)—40.3% (n = 27)—47.4% (n = 25)—34.7% p = 0.20, 1.6 [0.78–3.23]
Dialysis (n = 7)—5.4% (n = 4)—7.0% (n = 3)—4.2% p = 0.48, 1.7 [0.37–8.09]
Peripheral vascular disease (n = 94)—72.9% (n = 44)—77.2% (n = 50)—69.4% p = 0.33, 1.5 [0.67–3.30]
amongst others Indigenous population at risk of diabetes.
This study endeavoured to bridge these current knowledge
gaps, with particular focus on determining prevalence of and
identifying risk factors of limb amputations amongst patients
with DFU attending a typical Australian regional diabetes
foot clinic.
2. Methods
2.1. Eligibility Criteria. All patients attending the High Risk
Foot Clinic (HRFC) at Northeastern Australia’s Townsville
Hospital between January 1, 2011, and December 31, 2013,
were included in the study. Patients 18 years of age and over
with a confirmed diagnosis of either type 1 or type 2 diabetes
and coexisting DFU were included. Subjects under the age
of 18 and those with nondiabetic foot ulcers (e.g., trauma-
related, vasculitic, and neoplastic ulcers) were excluded from
the study. Subjects who attended the clinic for other man-
agement purposes (e.g., podiatry reviews, nail pathology, and
education about prevention) were also excluded.
2.2. Data Extraction. There were two main processes
involved in data extraction, including gathering of clinical
and biochemical data from patient profile. A retrospective
chart audit was initially performed, focusing on the cor-
respondence and outpatient attendance sections. The HRFC
pro forma sheet was then used to collect information regard-
ing the onset, duration, outcome, and type of ulcer defined
as ischaemic or nonischaemic based on University of Texas
Wound Classification System [21]. Furthermore, clinical
information on the diagnosis and management of diabetes,
coexisting macrovascular and microvascular complications,
and medication lists of the subjects was recorded. We also
obtained biochemical data using the hospital’s pathology
system, AUSLAB.Main parameters gathered included results
of full blood count, urea and electrolyte studies, lipid profiles,
Hba1c levels, and serum calcium, phosphate, and C-reactive
protein levels. Average figures over the three-year period
were calculated and included.
2.3. Data Analysis. SPSS software was utilised to perform
data analysis. Basic descriptive and frequency analyses of
the study sample were implemented to obtain demographic
characteristics, period prevalence of clinical outcomes and
diabetic complications, andmean age of the study population.
In addition, a combination of nonparametric and chi-squared
analyses was performed to identify differences in scaled data
and rank risk factors associated with amputation, respec-
tively. 𝑝 value of less than 0.05 was considered statistically
significant and together with odds ratios and confidence
intervals was included in our results. All significant values
were entered into binary logistic regression analysis and
correction for multiple regression logistic testing was then
conducted and factored in as part of our final results.
3. Results
3.1. Study Characteristics. A total of 129 subjects were
included in the analysis of this study, with 62.8% being male
(𝑛 = 81) and 37.2% female (𝑛 = 48) (refer to Table 1). The
mean age of the study cohort was 63.4 ± 14.1 years [CI 60.98–
65.89]. The Indigenous cohort comprised 17.8% (𝑛 = 23).
Patients were categorised according to comparison groups
of ischaemic (𝑛 = 57) and nonischaemic (𝑛 = 72) ulcers.
The period prevalence of amputation within the study sample
was 34.1% (𝑛 = 44), with 35.1% belonging to ischaemic (𝑛 =
20) and 33.3% nonischaemic (𝑛 = 24) cohorts. Amputation
occurred more commonly at a rate of 56.5% amongst the
Indigenous subjects, in comparison with 29.2% in the non-
Indigenous group, with a significant difference amongst the
ischaemic and nonischaemic ulcer cohorts (69.2% versus
30.8%). The mean age of amputation of 62.6 ± 12.5 years
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Table 2: Summary of biochemical parameters amongst the study cohort.
Biochemical variable Cohort 𝑝 value
Ischaemic ulcers Nonischaemic ulcers
Average Hba1c level 8.5% 9.0% 𝑝 = 0.06
Average CRP level 38.6 72.7 𝑝 = 0.14
Amputees Nonamputees
Average Hba1c level 9.0% 8.5% 𝑝 = 0.44
Average correct Ca2+ level 2.4mmol/L 2.3mmol/L ∗𝑝 = 0.00
Average serum creatinine level 156.2 𝜇mol/L 121 𝜇mol/L 𝑝 = 0.19
Males Females
Average serum creatinine level 155 𝜇mol/L 99.3 𝜇mol/L ∗𝑝 = 0.00
Average eGFR level 57.4mL/min 63.9mL/min 𝑝 = 0.22
Indigenous Non-Indigenous
Average white cell count 7.4 8.9 ∗𝑝 = 0.01
Average albumin level 37 34.2 𝑝 = 0.06
∗Statistically significant.
[CI 55.09–70.14] amongst the Indigenous cohort was similar
to their non-Indigenous counterparts, mean age of 62.0 ±
11.5 years [CI 57.81–66.25]. Amputation rates were much
higher amongst patients with PVD (39.4% versus 20%).
Males got amputated more frequently (59.1%) compared to
females (40.9%), although the mean age of male and female
amputees differed minimally at 61.0 years and 63.9 years,
respectively. Prevalence of ischaemic heart disease (IHD),
acute myocardial infarcts (AMI), CABG surgery, strokes,
and dialysis was significantly higher amongst ischaemic ulcer
patients, occurring at overall rates of 54.4%, 26.3%, 15.8%,
19.3%, and 7.0%, respectively.
3.2. Biochemical Parameters amongst the Study Cohort.
Using nonparametric analysis, corrected calcium levels
were calculated to be higher amongst the amputee cohort
(2.37mmol/L versus 2.26mmol/L (𝑝 = 0.003)) (refer to
Table 2) though clinically nonsignificant with normal range
2.15–2.60mmol/L. Similarly, although amputees were found
to have higher serum creatinine (156.21 𝜇mol/L versus
120.91 𝜇mol/L) and Hba1c (9.0% versus 8.5%) levels, these
results were statistically insignificant (𝑝 = 0.19 and𝑝 = 0.44).
Indigenous subjects had lower average white cell counts (𝑝 =
0.005) and higher albumin levels (𝑝 = 0.058). Males tended
to have poorer kidney function than females, with average
creatinine levels of 155.03 𝜇mol/L versus 99.25 𝜇mol/L (𝑝 =
0.003) and eGFR levels of 57.94mL/min versus 63.90mL/min
(𝑝 = 0.22).
3.3. Clinical Risk Factors Associated with Amputation. Chi-
squared analysis identified diabetic retinopathy (𝑝 = 0.00,
OR 4.4 [2.15–12.75]), Indigenous background (𝑝 = 0.01, OR
3.1 [1.17–9.16]), Charcot’s arthropathy (𝑝 = 0.01, OR 2.9 [1.38–
9.29]), longer diabetes duration, defined as 15 years or longer
(𝑝 = 0.03, 2.2 [1.00–4.86]), dyslipidaemia (𝑝 = 0.04, 3.4
[0.94–12.38]), neuropathy (𝑝 = 0.03, 3.3 [1.05–10.26]), PVD
(𝑝 = 0.04, 2.6 [1.03–6.55]), and CABG surgery (𝑝 = 0.01, OR
4.1 [1.81–30.76]) to be significantly associated with increased
risk of amputation, amongst others (refer to Table 3). Binary
logistic regression analyses identified retinopathy, CABG
surgery, Charcot’s arthropathy, and Indigenous background
as the most significant risk factors for amputation (refer
to Table 4). Clinical parameters that fell short of statistical
significance include smoking history (𝑝 = 0.49), dialysis
(𝑝 = 0.62), diabetes type (𝑝 = 0.46), male sex (𝑝 = 0.53),
multiple-ulcer history (𝑝 = 0.15), previous history of DFUs
(𝑝 = 0.06), and ulcer type (𝑝 = 0.84) and grade (𝑝 = 0.93).
4. Discussion
4.1. Prevalence of Lower Limb Amputations. In this clinic-
based case control study we have demonstrated prevalence of
amputation in our study population to be 34.1%, a figure that
is considerably higher in comparison with others’ findings
of 15.4% to 21.4% [22, 23]. On the other hand our report
conforms to Miner and Kirsner and Amogne et al. report
of higher rate of LLA in their respective diabetic foot clinic
populations [13, 24]. The high prevalence might be related
to inclusion of the population at the highest risk of the
disease and its complications [25]. In this study, Indigenous
Australians were found to be at greater risk of diabetic LLA,
which is in keepingwith others’ observation [20, 26]. Further-
more, whilst there was a marginal difference in amputation
between ischaemic and nonischaemic cohorts in the overall
group, amputations related to ischaemic ulcers were more
than double amongst the Indigenous subgroup. Essentially,
the prevalence of amputation amongst our subjects stood at
comparatively higher numbers and occurred predominantly
amongst Indigenous subjects with ischaemic ulcers.
4.2. Risk Factors for Lower Limb Amputations. We identified
numerous clinical factors that correlate with higher amputa-
tion risk,most in keepingwith previous literature, in addition
to new, undocumented parameters.Themost significant con-
tributing factors were diabetic retinopathy, CABG surgery,
Charcot’s foot, and Indigenous ethnicity. Whilst Ndip et al.
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Table 3: Summary of risk factors for lower limb amputation
amongst the cohort using chi-squared analysis.
Risk factor 𝑝 value, OR [CI]
Acute myocardial
infarction 𝑝 = 0.20, 1.8 [0.74–4.16]
Antihypertensive
medications 𝑝 = 0.28, 1.8 [0.62–5.32]
Cellulitis ∗𝑝 = 0.00, 3.3 [1.54–7.21]
Cerebrovascular accidents 𝑝 = 0.07, 2.5 [0.93–6.67]
Charcot’s arthropathy ∗𝑝 = 0.01, 2.9 [1.29–6.70]
Chronic kidney disease 𝑝 = 0.27, 1.5 [0.72–3.16]
Coronary artery bypass
graft surgery
∗
𝑝 = 0.01, 4.1 [1.29–13.17]
Depression 𝑝 = 0.05, 2.2 [0.98–5.10]
Dialysis 𝑝 = 0.62, 1.5 [0.32–6.94]
Dyslipidaemia ∗𝑝 = 0.04, 3.4 [0.94–12.38]
eGFR < 45mL/min 𝑝 = 0.08, 2.1 [0.91–4.73]
Foot antibiotics ∗𝑝 = 0.04, 2.3 [1.03–4.98]
Gastrooesophageal reflux
disease (GORD) 𝑝 = 0.34, 1.5 [0.67–3.15]
Haemoglobin < 8 g/dL 𝑝 = 0.46, 1.7 [0.42–6.64]
Hba1c > 7.5% 𝑝 = 0.92, 1.1 [0.40–2.73]
Hypertension 𝑝 = 0.41, 1.6 [0.50–5.43]
Hypoalbuminaemia 𝑝 = 0.73, 0.9 [0.37–1.99]
Indigenous ethnicity ∗𝑝 = 0.01, 3.1 [1.25–7.92]
Infection severity
(mod-severe)
∗
𝑝 = 0.02, 0.4 [0.18–0.89]
Insulin treatment 𝑝 = 0.12, 1.9 [0.85–4.28]
Ischaemic heart disease 𝑝 = 0.24, 1.6 [0.75–3.24]
Ischaemic ulcer type 𝑝 = 0.84, 1.1 [0.52–2.25]
Longer duration of diabetes ∗𝑝 = 0.03, 2.2 [1.00–4.86]
Male sex 𝑝 = 0.53, 0.8 [0.37–1.66]
Multiple ulcers 𝑝 = 0.15, 0.6 [0.25–1.25]
Nephropathy 𝑝 = 0.15, 1.7 [0.82–3.56]
Neuropathy ∗𝑝 = 0.03, 3.3 [1.05–10.26]
Obesity 𝑝 = 0.09, 0.5 [0.23–1.13]
Osteomyelitis ∗𝑝 = 0.00, 3.9 [1.54–10.07]
Peripheral vascular disease ∗𝑝 = 0.04, 2.6 [1.03–6.55]
Previous history of ulcers 𝑝 = 0.06, 2.1 [0.98–4.41]
Retinopathy ∗𝑝 = 0.00, 4.4 [1.99–9.59]
Smoking history 𝑝 = 0.49, 0.8 [0.37–1.60]
Statin therapy 𝑝 = 0.06, 2.7 [0.95–7.78]
Type of diabetes 𝑝 = 0.46, 1.4 [0.56–3.65]
Wound classification 𝑝 = 0.93, 1.1 [0.30–3.78]
∗ denotes being statistically significant.
provide data linking diabetic retinopathy to increased risk
of DFU development [27], ours is the first study to identify
retinopathy not only as a contributing factor, but also as
the most significant factor leading to amputation amongst
DF patients, accentuating the importance of early detection
and management of diabetic complications. McEwen et al.
Table 4: Risk factors associated with lower limb amputation in the
study population [logistic regression analysis].
Risk factor 𝑝 value, OR [CI]
Coronary artery bypass graft surgery 𝑝 = 0.01, 7.5 [1.81–30.76]
Indigenous ethnicity 𝑝 = 0.02, 3.3 [1.17–9.16]
Charcot’s arthropathy 𝑝 = 0.01, 3.6 [1.38–9.29]
Retinopathy 𝑝 = 0.00, 5.2 [2.15–12.75]
found no associationwith retinopathy but reported a 2-3-fold
amputation risk amongst patients with diabetic neuropathy
[28], results that are consistent with ours, which isolate
neuropathy and dyslipidaemia as significant risk factors for
amputation.We identified PVDwith increased risk of adverse
outcome, also supported by current literature, which labels
it as a causal factor for amputation and mortality amongst
diabetics [29–32]. We have additionally extended existing
knowledge by highlighting CABG surgery as a novel risk
factor for amputation, which supports the role of both
microvascular and macrovascular disease as significant risk
factors for LLA in subjects with diabetic foot ulcer.
Interestingly, there has been conflicting data on the role
of ethnicity in the outcome of DFUs. Whilst multiple studies
found unremarkable figures in amputation rates amongst a
multiracial cohort [27, 28], Lavery et al. found a significant
difference in both prevalence and ulcer severity contribut-
ing to amputation amongst African American cohorts in
other parts of the world [33]. Correspondingly, we have
found Indigenous ethnicity to be amongst the strongest
contributing factors in our cohort, who were almost twice
as likely to undergo an amputation. The higher prevalence of
amputations in the group of Indigenous Australians could be
attributed to a genetic predisposition or to a socioeconomic
status that drives the patients to present late for clinical care.
This result is supported by previous Australian data stating
that Indigenous Australians are known to develop diabetes
and its associated metabolic complications at a younger age
[24, 34]. As the first study to be conducted in Northeastern
Australia which hosts some of the largest Indigenous peoples
nationwide, our results hold considerable significance for the
local population, given that longer diabetes duration was
flagged as a contributor for adverse outcome and highlights
the need for earlier detection and management amongst
Indigenous Australians [32, 35, 36].
Our results identified other risk factors of LLA in sub-
jects with DFU including Charcot’s arthropathy, a history
of osteomyelitis, and severity of foot infection or cellulitis
requiring antibiotic treatment.Our result was in keepingwith
the previously reported 30% rate of amputation in subjects
with Charcot’s arthropathy, placing DFU patients at a 12
times higher lifetime risk of amputation [37, 38]. Similarly,
in keeping with our findings, Wukich et al. have linked
history of cellulitis and moderate-to-severe foot infection
to amputation [39]. There is notably no current evidence
suggesting use of antibiotics to prevent infections in sub-
jects with DFU at risk of LLA in spite of our findings of
antibiotics use preceding amputation. The tropical climate
of Northeastern Australia is a likely contributor to this
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association, resulting in increased rates of bacterial skin
and soft tissue infections requiring ongoing antimicrobial
treatment. Moreover, a new association was also found with
depression, suggesting that psychological health can be an
indicator of healing and recovery in physical illness. Given
that the DFU is known to have a biopsychosocial impact
on its patients, this information accents the importance of a
multidisciplinary team approach in treating the individual as
a whole and calls for additional research in the area.
In contrast to others’ observation, we found no associa-
tion between renal disease and amputation risk, specifically
with CKD and dialysis, all of which have previously been
linkedwith amputation [35, 40]. Amongst our dialysis cohort,
all seven subjects were male, with one having Indigenous
background. These characteristics were similar to Lavery et
al.’s study, whose dialysis cohort mainly focused on a non-
Hispanic Caucasian population, yet whilst they identified
more limb amputations amongst their renal disease sub-
group, we found no significant association between the two
[41]. This could be explained by the nature of our study
cohort, which focused onDFUpatientswith concurrent renal
disease rather than a specific CKD or dialysis population,
thereby missing a number of diabetic LLA patients that
either did not meet the criteria or failed to attend the
HRFC. Intensive glycaemic control has been established as
an important prognostic healing factor and found to reduce
diabetes-related mortality [42, 43]. However when discussed
in linkage with lower extremity complications, some studies
report a 20%higher risk of amputation amongst subjects with
Hba1c levels above 7.5% similar to our findings but in contrast
to Winkley et al. who reported Hba1c levels below 7.5% as
having higher mortality and increased risk of amputation
[31, 32, 44]. In light of this conflicting report further research
is required to characterise the findings.
The period prevalence of IHD and AMI amongst the
study cohort was similar to others’ report indicating high
prevalence of cardiovascular disease and its complications
amongst the DF cohort [45]. CKD and dialysis were present
in 40.3% and 5.4%, which was once again lower compared to
international data and again likely due to the fact that ours
was not a renal-specific cohort. We did, however, establish
higher rate of PVD (72.9%) compared to Setacci et al.,
who reported a period prevalence of up to 30% amongst
the diabetic cohort [46], which reinforces the role of PVD
in contributing to amputation. Furthermore, 14.7% of the
population had a background history of strokes, with no
previous studies available with which to make comparisons.
Our results have appropriately highlighted that the high
rates of adverse multisystemic, vascular outcomes amongst
patients with the DF necessitate a multidisciplinary approach
in treatment delivery.
4.3. Strengths and Limitations. Major study strength included
the data extraction process, which utilised a wide range of
demographic, clinical, and biochemical data to formulate
an extensive analysis to support the study aims. This study
implemented a highly focused study cohort with a good rep-
resentation of Indigenous subjects to evaluate and compare
our results with international data. It is important to note
that there is a limitation to retrospective studies in general.
Observations derived from such studies may contain some
missing information and thus may serve as a stimulus to
further prospective work to clarify findings.The present work
must be interpreted in the knowledge of the defects inherent
in such studies. Nevertheless, our result is in agreement with
other reports [20, 22, 47].
5. Conclusions
We have documented high prevalence of lower limb ampu-
tation in our study population. In keeping with our hypoth-
esis, the ischaemic ulcer cohort demonstrated higher rates
of adverse clinical outcomes, including IHD, strokes, and
renal disease. Numerous known and novel demographic
and clinical risk factors were coupled with amputation, the
most significant of them being Indigenous ethnicity, dia-
betic retinopathy, Charcot’s arthropathy, and CABG surgery.
Whilst there were no significant differences in amputation
prevalence between the ischaemic and nonischaemic groups
in the overall cohort, Indigenous subjects with ischaemic
ulcers were amputated much more frequently. Extended
research in the local area is encouraged to study factors lead-
ing to selectively higher amputation rate in the Indigenous
population.We havemade a huge development in identifying
predisposing characteristics amongst DF patients, but our
knowledge is not yet comprehensive to enable us to prevent
limb amputation in the high risk diabetic population.
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